Comparison of efficacy of first- versus second-line adalimumab in patients with rheumatoid arthritis: experience of the Italian biologics registries
Academic Article
Publication Date:
2017
abstract:
Targeted drugs against key pathogenetic molecules such as TNF-alpha have significantly improved outcomes in rheumatoid arthritis (RA). They are widely used in clinical practice and drug registries give us information to support their use. Adalimumab (ADA) is able to induce a comprehensive disease control in RA by achieving clinical, functional and radiographic control.
Iris type:
14.a.1 Articolo su rivista
Keywords:
Adalimumab; Adrenal Cortex Hormones; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Female; Humans; Italy; Male; Methotrexate; Middle Aged; Remission Induction; Severity of Illness Index; Treatment Failure; Registries
List of contributors:
Codullo, Veronica; Iannone, Florenzo; Sinigaglia, Luigi; Favalli, Ennio Giulio; Sarzi-Puttini, Piercarlo; Atzeni, Fabiola; Ferraccioli, Gianfranco; Gremese, Elisa; Carletto, Antonio; Giollo, Alessandro; Govoni, Marcello; Bergossi, Francesca; Galeazzi, Mauro; Cantarini, Luca; Salaffi, Fausto; Di Carlo, Marco; Bazzani, Chiara; Pellerito, Raffaele; Sebastiani, Marco; Ramonda, Roberta; Lapadula, Giovanni; Caporali, Roberto
Published in: